GLOW Stack Stack Protocol

Stack Overview

The GLOW Stack is the Wolverine Stack (BPC-157 + TB-500) with GHK-Cu added. The addition of the copper tripeptide shifts the protocol's center of gravity away from pure soft-tissue repair and toward skin quality, scar remodeling, hair density, and broader connective-tissue regeneration. The name is a user-community label, not a branded product — though multiple research-chemical suppliers sell a pre-blended 70 mg vial at the canonical 5:1:1 ratio (50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500).

Who this is for: adults with visible photoaging, post-surgical scarring they want to remodel, post-acne scarring, thinning hair on the vertex or temples, and chronic mild skin inflammation (rosacea-adjacent, eczema-adjacent). Also people recovering from a musculoskeletal injury who want connective-tissue and skin benefits on the same cycle — the protocol rewards that kind of combined goal better than running each peptide solo.

Who this is not for: anyone with active melanoma or a high melanoma-risk profile (the pro-angiogenic signaling common to GHK-Cu and BPC-157 is the shared concern); Wilson's disease or other copper-overload conditions; active malignancy; pregnancy or lactation; anyone expecting dramatic cosmetic transformation in 4 weeks. Effects are gradual and cumulative.

Honest framing: as with Wolverine, no randomized controlled trial has tested this three-peptide combination in humans. GHK-Cu has decades of topical cosmeceutical data; BPC-157 and TB-500 have extensive preclinical repair data. The combined injected protocol is mechanistic rationale plus community experience, not trial-validated.

Mechanism of Synergy

The three peptides engage partially independent arms of the tissue-repair and skin-remodeling program. The mechanistic rationale for combination draws on the following:

• Matrix synthesis + vascular supply + cell delivery + anti-fibrotic bias — GHK-Cu stimulates fibroblast collagen / elastin / GAG synthesis and broad gene-expression reset; BPC-157 drives VEGFR2 / eNOS-mediated new capillary formation that supplies the newly built matrix; TB-500 moves repair cells through the tissue via G-actin-sequestration-mediated cell migration and biases remodeling toward regenerative rather than scar-dominant closure. All four inputs are needed for efficient dermal matrix build-out.
• Copper cofactor convergence — GHK-Cu delivers copper to lysyl oxidase (cross-links newly synthesized collagen into mature fibrils) and to superoxide dismutase 1 (protects the new matrix from oxidative degradation). Without adequate copper delivery, new collagen builds without durable cross-linking. BPC-157's angiogenic effect improves oxygen and nutrient delivery; TB-500's cell-migration support recruits fibroblasts into the work site.
• Scar-biased vs regeneration-biased repair — TB-500's anti-fibrotic signal plus GHK-Cu's MMP / TIMP modulation shift healing away from dense fibrotic scar and toward organized regenerative tissue. This is why the stack is frequently reported for scar-remodeling applications.
• Hair-follicle overlap — GHK-Cu has direct hair-follicle-stimulating data (Pyo et al. 2007, Arch Pharm Res); BPC-157 and TB-500 support broader scalp vascular supply and follicle-cycling biology. Users run GLOW specifically for hair density with mechanistic coverage across multiple pathways.
• Topical + injected dual route — GHK-Cu topical serums have independent cosmetic-trial evidence. Combining daily topical GHK-Cu with cycled injected GLOW is a common practitioner approach for face-specific goals.

The Components

Why they pair: GHK-Cu drives matrix synthesis (collagen, elastin, GAGs) and broad gene-expression reset; BPC-157 supplies the vasculature that feeds the new matrix; TB-500 moves the repair cells and biases remodeling away from scar. Matrix synthesis + vascular supply + cell delivery + anti-fibrotic tone — the four pillars of regenerative skin and connective-tissue repair.

What the Research Shows

No randomized controlled trial has tested the three-peptide GLOW combination in humans. The evidence below covers the individual components and the mechanistic framework.

• No combined-stack human trial — A search of ClinicalTrials.gov and PubMed for combined "GHK-Cu + BPC-157 + TB-500" returns no registered trials or peer-reviewed clinical evidence as of April 2026.
• GHK-Cu topical cosmetic evidence (strongest leg) — Multiple 12-week placebo-controlled cosmetic facial trials report measurable improvements in collagen density, skin thickness, firmness, and fine-line reduction (Abdulghani 1998; Leyden 2002; subsequent). Review: Pickart and Margolina 2018, PMID 29986520.
• BPC-157 preclinical tissue-repair evidence — Extensive rodent data for tendon, ligament, and gastrointestinal tissue healing (Sikiric group; Staresinic et al. 2003 Achilles transection, PMID 14554208). Multiple small human pilots for tendon and GI indications.
• TB-500 preclinical evidence — Thymosin beta-4 family has published wound-healing, anti-fibrotic, and angiogenesis data. Philp et al. 2004 (PMID 15037008) on angiogenesis and hair-follicle development. RegeneRx Phase 3 ophthalmic programs with the related molecule.
• Combined protocol — community experience only — Dermatology practitioners and community users report consistent improvements in skin quality, scar remodeling, and hair density on the combined protocol. This is uncontrolled evidence heavily confounded by baseline skincare, procedural adjuncts, sun exposure, and reporter selection.
• Topical retinoid remains the single most evidence-backed topical anti-aging intervention — No peptide stack substitutes for tretinoin + SPF + sleep + protein. GLOW layers on top of those foundations.

Human Data (Individual Components)

Human evidence exists for the individual components but not for the combined stack.

• GHK-Cu topical cosmetic trials — Multiple 12-week placebo-controlled studies (Abdulghani 1998; Leyden 2002) report measurable improvements in skin collagen density, firmness, and fine-line reduction. Published cosmetic-trial literature is the strongest human evidence in the stack.
• GHK-Cu in chronic wound healing — Early-1990s ProCyte clinical work demonstrated improved healing of venous stasis ulcers and pressure ulcers with topical GHK-Cu formulations.
• GHK-Cu for hair — Small clinical studies on topical / intradermal GHK-Cu report increased hair density and terminal-hair conversion.
• BPC-157 human pilots — A small number of human pilot studies have explored BPC-157 for inflammatory bowel disease and for knee / tendon pain. Results are encouraging but studies are small and not placebo-controlled at scale.
• TB-500 — RegeneRx ophthalmic program — Related thymosin-β4 molecule (RGN-259) has advanced through Phase 2 / 3 ophthalmic trials for dry eye and neurotrophic keratopathy. Cardiac and skin-repair programs have not advanced to large Phase 3.
• No combined RCT — No published randomized trial of the three-peptide combination.

Dosing Protocol & Reconstitution

GLOW is almost always run as the 70 mg pre-blended vial — 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 in a 5:1:1 ratio. Separate vials are possible but uncommon because the 5:1:1 proportion matches community standard well.

Standard community protocol: 0.08–0.1 mL (8–10 units) SubQ daily from the 2 mL pre-blend reconstitution. The 8-unit draw delivers 2 mg GHK-Cu + 400 mcg each of BPC-157 and TB-500; the 10-unit draw delivers 2.5 mg + 500 mcg + 500 mcg. Many users settle at 10 units for the first month and adjust to 8 units if GHK-Cu-related local irritation develops.

Lower-dose variant (3 mL BAC): some users prefer the 3 mL reconstitution to land closer to the research-validated BPC-157 dose (~300 mcg). 10 units from the 3 mL reconstitution gives 1.67 mg GHK-Cu + ~330 mcg of each peptide.

Reconstitution check — blue tint matters. The GHK-Cu complex gives a characteristic faint blue color. A colorless "GHK-Cu" solution indicates dissociation, degradation, or mislabeling. Reject it.

Technique: 29G–31G insulin syringe. SubQ 45° into abdomen or thigh. Rotate sites. Topical GHK-Cu (1–2% serum) is applied to clean skin twice daily if added for face-specific goals.

→ Use the Kalios Peptide Calculator for exact syringe units

Sample Weekly Schedule & Cycle Structure

Standard 5-on / 2-off schedule using the 70 mg pre-blend reconstituted in 2 mL BAC (35 mg/mL combined):

Total: 5 injections per week. Weekly totals: 12.5 mg GHK-Cu, 2.5 mg BPC-157, 2.5 mg TB-500. One 70 mg vial lasts ~14 days at this cadence (0.5 mL drawn per week out of 2 mL reconstituted).

• Loading (weeks 1–6) — 5x/week injected pre-blend. Topical GHK-Cu AM + PM. Most matrix-synthesis signaling occurs in this window.
• Maintenance (weeks 7–12) — 3x/week injected. Topical unchanged. Remodeling-phase emphasis; less injection burden.
• Washout (weeks 13–16, minimum 4 weeks) — Stop injected peptides. Continue topical GHK-Cu if tolerated. Lets you see which gains persist (tissue-level remodeling) vs which fade (circulating effect).
• Re-cycle — For chronic / multi-target goals (aging skin, hair, multiple scars), 2–3 cycles per year is a common cadence. One cycle rarely saturates the benefit.
• Timing with procedures — Some clinicians time a GLOW cycle to bridge a cosmetic procedure (microneedling, fractional laser, chemical peel), using the peptides to enhance post-procedure remodeling. Begin 1–2 weeks pre-procedure; continue 8+ weeks after.
• Topical vs injected rationale — Topical GHK-Cu works for surface cosmesis. Injected is needed for systemic effect (hair density, connective tissue, scar remodeling at depth). Running both is the highest-coverage approach.

Reconstitution & Storage

Pre-blend and standalone vials are supplied as lyophilized powder, typically 10–70 mg per vial. The GHK-Cu component gives the pre-blend solution a faint blue tint after reconstitution.

• Reconstitution — Inject bacteriostatic water slowly down the inside wall of the vial at 45°. Swirl gently — never shake. The 70 mg pre-blend vial reconstitutes to a clear, faintly blue solution.
• Blue-tint QC check — Colorless or off-white pre-blend solution after reconstitution indicates GHK-Cu degradation or mislabeling. Reject.
• Storage — Lyophilized stable at 2–8°C refrigerated; room-temperature tolerable short-term. Reconstituted: 2–8°C refrigerated, used within 28 days. Do not freeze reconstituted.
• Light sensitivity — Store out of direct light. GHK-Cu copper complex is moderately light-sensitive.
• Topical formulations — Standalone cosmetic-grade GHK-Cu serums at 0.1–2% peptide concentration. Avoid applying topical GHK-Cu and high-concentration ascorbic acid in the same application (vitamin C reduces Cu²⁺ and destabilizes the complex — AM / PM separation is standard).

→ Use the Kalios Peptide Calculator for exact syringe units

Side Effects & Risks

• GHK-Cu — Mild injection-site blue tint (copper color); usually resolves within minutes. Rare copper-related scalp itch at high topical doses. Very rare copper-overload symptoms with chronic high-dose systemic use — not documented at typical GLOW doses.
• BPC-157 / TB-500 — Same profile as the Wolverine Stack. Mild nausea, injection-site soreness, occasional loading-phase flu-like fatigue. Both peptides are generally well-tolerated in community use.
• Combined protocol — No unique additive side effects documented beyond what each component contributes. Injection-site rotation matters; the GLOW vial concentrations mean more total peptide per injection than straight BPC-157 alone.
• Melanocytic concern — Users with significant nevus burden, personal melanoma history, or strong family history should consult dermatology before running. Not because GHK-Cu specifically is carcinogenic (it is not), but because the pro-angiogenic mechanism shared across the stack warrants caution with active or high-risk melanocytic lesions.
• Copper-overload conditions — Wilson's disease is a contraindication. Monitor serum copper and ceruloplasmin if running multiple cycles per year.
• Other active malignancy — Pro-angiogenic mechanisms warrant caution; discuss with oncology before use.
• Pregnancy / lactation — Not studied; avoid.
• WADA — BPC-157 banned S0, TB-500 banned S2 — Tested athletes face sanction for any detected use. Detection methods are established.
• Baseline monitoring — CMP + CBC. Ferritin (copper-iron interaction). Consider serum copper / ceruloplasmin for chronic use.
• Subjective tracking — Standardized photographs (same lighting, same distance, same time of day) every 2 weeks. Progression is slow enough that memory-based self-assessment is unreliable.
• Red flags to stop — New skin rash beyond injection site, persistent blue-green discoloration of skin or nails (copper deposition), new darkening of moles, unexplained hair loss (rare paradoxical effect), or any unexplained new symptom.

Bloodwork & Monitoring

• Baseline CMP and CBC — Liver, kidney, and hematologic function before starting any chronic parenteral peptide protocol.
• Serum copper + ceruloplasmin — For users on repeated annual GLOW cycles; document baseline and recheck at 12 weeks if running >2 cycles per year.
• Ferritin and iron studies — Copper, iron, and zinc compete at intestinal transporters; track ferritin if chronic.
• hsCRP / inflammatory baseline — Optional; allows tracking of chronic inflammatory component if skin condition is inflammation-driven (rosacea-adjacent).
• Standardized photography — Baseline, at 6 weeks, at 12 weeks, at washout end. Same lighting, angle, distance. This is the most reliable outcome measure for cosmetic endpoints.
• Hair-density photography — If hair is a target endpoint; frontal, vertex, and parting views at the same intervals.
• Skin-cancer surveillance — Age-appropriate dermatology check before starting chronic cycling.

Substitutions & Alternatives

→ Check compound compatibility in the Stack Builder

What to Expect — Timeline

• Week 1–2 — Subtle. Skin may feel slightly smoother, more hydrated. Morning puffiness may reduce. Internal inflammation markers may start to shift for users who track them. No visible cosmetic change yet.
• Week 3–4 — First visible changes in responders: skin "brightness," reduced fine-line prominence in bright light, slight improvement in skin-tone unevenness. Still below the threshold of noticeable-to-others for most users.
• Week 5–8 — Primary response window. Reported: scar quality improvement (softer, flatter, better color match), reduced redness of rosacea-adjacent skin, visible improvement in skin firmness, early hair-density changes in responders. Sleep-quality improvements sometimes emerge in this window (BPC-157 and TB-500 overlap with GHK-Cu's broad anti-inflammatory signaling).
• Week 9–12 — Consolidation. Peak gains for most users. Hair responders notice density changes clearly. Scar remodeling is typically still in progress; scars often continue improving for weeks after cycle end.
• Washout (weeks 13–16) — Gains typically hold. Skin / matrix changes are structural remodeling rather than circulating-drug effects, so they do not unwind on discontinuation.
• Hair-specific caveats — Hair cycles are long (follicle-to-visible-growth takes 3–6 months). Real hair-density answers require at least two consecutive cycles separated by the 4-week washout. One cycle is inconclusive for hair.
• Non-responders — Real. Community reports suggest ~20–30% see no visible cosmetic change. Common factors: photoaging severity (harder to reverse than chronological aging), baseline chronic inflammation / smoking / poor sleep, product quality, and absence of adjunct topical or procedural support.

Practical User Notes

• Topical + injected is the highest-coverage protocol — Run 1–2% topical GHK-Cu AM and PM regardless of whether you inject. The topical evidence is the strongest in the stack.
• The vial should be blue — Proper GHK-Cu solution is a faint blue from the copper complex. A colorless "GHK-Cu" vial is either degraded or mislabeled. Reject it.
• Inject PM for skin goals — Overnight repair phase aligns with peptide availability peaks. Not evidence-based, just community convention.
• Don't mix topical GHK-Cu with vitamin C serum — Ascorbic acid reduces Cu²⁺ and destabilizes the GHK-Cu complex. Apply vitamin C AM, GHK-Cu PM.
• Don't mix topical GHK-Cu with retinoids in the same application — Irritation plus copper-complex instability. Alternate nights or separate by hours.
• Sunscreen every morning, always — GLOW plus UV damage is a losing bet. SPF 30+ daily is the highest-leverage adjunct to any skin peptide protocol.
• Hair patience — Follicle cycles are months. Do not judge hair response before cycle 2. Before-and-after photographs (same lighting, same angle) every 4 weeks.
• Protein matters — Collagen synthesis is protein-limited. 1.6–2.0 g/kg/day protein intake is a prerequisite for matrix-building peptides to have material to work with.
• Alcohol is antagonistic — Chronic alcohol impairs collagen cross-linking via hepatic copper and zinc perturbation. Moderate during cycles.
• Sterile technique, always — Infection ruins a cycle faster than anything else.
• Source with COA — GHK-Cu is easy to fake (any blue peptide looks right). Independent HPLC + mass spec + metal analysis confirms the copper complex. Trust only vendors with third-party COA.
• Photograph monthly — Subjective memory is unreliable on cosmetic endpoints. Standardize lighting, distance, angle. Review at cycle end.

Regulatory Status

Related Compounds

People researching the GLOW Stack often also look at these:

Next Steps

Key References

No clinical trial has studied the GHK-Cu + BPC-157 + TB-500 combination in humans. References below cover the individual components and the mechanistic framework.

1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. PMID: 29986520. (Comprehensive GHK-Cu review.)
2. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. PMID: 26236730.
3. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺. FEBS Lett. 1988;238(2):343-346. PMID: 3169264.
4. Maquart FX, Bellon G, Chaqour B, Wegrowski J, Patt LM, Trachy RE, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺ in rat experimental wounds. J Clin Invest. 1993;92(5):2368-2376. PMID: 8227353.
5. Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834-839. PMID: 17702486.
6. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. PMID: 21548867.
7. Staresinic M, Sebecic B, Patrlj L, Jadrijevic S, Suknaic S, Perovic D, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon. J Orthop Res. 2003;21(6):976-983. PMID: 14554208.
8. Sikiric P, Seiwerth S, Rucman R, Kolenc D, Vuletic LB, Drmic D, et al. Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865. PMID: 27228452.
9. Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4. Proc Natl Acad Sci USA. 1981;78(2):1162-1166. PMID: 6940133.
10. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration. Nature. 2004;432(7016):466-472. PMID: 15565145.
11. Philp D, Goldstein AL, Kleinman HK. Thymosin beta 4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115. PMID: 15037008.
12. Pollard JD, Quan S, Kang T, Koch RJ. Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts. Arch Facial Plast Surg. 2005;7(1):27-31. PMID: 15655171.
13. Hostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflamm Res. 2011;60(1):79-86. PMID: 20835751.
14. Campbell JD, McDonough JE, Zeskind JE, Hackett TL, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Med. 2012;4(8):67. PMID: 22937864.
15. FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) — 503A / 503B. FDA.gov, updated 2025-2026.
16. WADA Prohibited List 2026. Sections S0 and S2. World Anti-Doping Agency.

→ Use the Kalios Peptide Calculator for exact syringe units